Gemcitabine CAS 95058-81-4
Introduction：Basic information about Gemcitabine CAS 95058-81-4, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Gemcitabine Basic informationDescription References
| Product Name: | Gemcitabine |
| Synonyms: | GEMCITABINE HCL USP;2'-Deoxy-2',2'-difluoro-D-cytidine;2''-DEOXY-2'',2''-DIFLUOROCYTIDINE(GEMCITABINE);2',2'-Difluorodeoxycytidine;Cytidine, 2'-deoxy-2',2'-difluoro-;gemicitabine;NSC 613327;gencitabine base |
| CAS: | 95058-81-4 |
| MF: | C9H11F2N3O4 |
| MW: | 263.2 |
| EINECS: | 619-100-6 |
| Product Categories: | Inhibitors;Antineoplastic;API;Antineoplastic drug, difluorine nucleoside analog |
| Mol File: | 95058-81-4.mol |
Gemcitabine Chemical Properties
| Melting point | 168,64 C |
| alpha | 365 +425.36°; D +71.51° |
| Boiling point | 482.7±55.0 °C(Predicted) |
| density | 1.84±0.1 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | Methanol (Slightly), Water (Slightly, Heated) |
| form | Solid |
| pka | 11.65±0.70(Predicted) |
| color | White to Off-White |
| InChI | InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 |
| InChIKey | SDUQYLNIPVEERB-QPPQHZFASA-N |
| SMILES | OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](F)(F)[C@@H]1O |
| CAS DataBase Reference | 95058-81-4(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xn,Xi |
| Risk Statements | 21-36/38-46-62-63 |
| Safety Statements | 25-26-36/37-53 |
| HS Code | 29349990 |
| Hazardous Substances Data | 95058-81-4(Hazardous Substances Data) |
| Toxicity | LD10 i.v. in rats: 200 mg/m2 (Abbruzzese) |
| Description | Gemcitabine (2’,2’-difluorodeoxycytidine; dFdCyd) is a novel deoxycytidine analogue with both structural and metabolic similarities to cytarabine. It has a broad spectrum of antitumor activity in preclinical murine leukemia and solid tumor models. This drug requires intracellular phosphorylation that results in the accumulation of difluorodeoxycytidine triphosphate (dFdCTP). The dFdCTP competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA, which in turn inhibits DNA synthesis and terminates DNA chain elongation. In addition, this drug reduces intracellular deoxynucleoside triphosphate pools, presumably through the inhibition of ribonucleotide reductase. Gemcitabine is used alone or with other treatments/medications to treat certain types of cancer (including breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, bladder cancer, bone cancer, Ewing’s sarcoma, mesenchymal chondrosarcoma osteosarcoma, dedifferentiated chondrosarcoma, head and neck cancers-cancer of the nasopharynx, hepatobiliary cancers including gallbladder cancer, Hodgkin lymphoma, kidney cancer, malignant pleural mesothelioma, non Hodgkin lymphoma, non-melanoma skin cancer – dermatofibrosarcoma protuberans (DFSP), occult primary, small cell lung cancer, soft tissue sarcoma, testicular cancer, thymic malignancies, uterine malignancies). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. One commercial product of gemcitabine is Gemzar, which is supplied in a sterile form for intravenous use only. |
| References | [1] H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, M. C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, R. Nelson, F. A. Dorr, C. D. Stephens, D. D. Von Hoff (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, 15, 2403-2413 [2] http://www.webmd.com/drugs/2/drug-13451/gemcitabine-intravenous/details |
| Description | Gemcitabine is an anticancer nucleoside analog that inhibits the growth of HL-60 promyelocytic leukemia cells with an LC50 value of 40 nM. It inhibits the growth of MX-1 mammary, CX-1, HC-1, GC3, and VRC5 colon, LX-1, Calu-6, and NCI-H460 lung, and HS766T, PaCa-2, PANC-1, and BxPC-3 pancreatic cancer tumors in mouse xenograft models (45-93% inhibition). Gemcitabine is a prodrug that is metabolized to a diphosphate and triphosphate form in cells. The triphosphate form is incorporated into DNA which induces masked chain termination and cell death. By specifically inhibiting growth arrest and DNA damage inducible protein 45 a (Gadd45a), a key mediator of active DNA demethylation, gemcitabine, at concentrations ranging from 34 to 134 nM, inhibits repair-mediated DNA demethylation in a methylation-sensitive reporter assay. Gemcitabine also has broad antiretroviral activity, decreasing MuLV cell infectivity, a murine AIDS model, in cell culture (EC50 = ~1.5 nM) and inhibits the progression of murine AIDS in vivo at a dose of 1-2 mg/kg per day. |
| Originator | Gemzar,Lilly Co. |
| Uses | Gemcitabine is used for breast cancer treatment. First-line treatment for locally advanced pancreatic cancer. |
| Uses | Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites. It is used alone or in combination with other medicines to treat cancer of the breast, ovary, pancreas, and lung. Gemcitabine interferes with the growth of cancer cells, which a |
| Indications | Gemcitabine (Gemzar), an antimetabolite, undergoesmetabolic activation to difluorodeoxycytidine triphosphate,which interferes with DNA synthesis and repair.It is the single most active agent for the treatment ofmetastatic pancreatic cancer, and it is used as a first-linetreatment for both pancreatic and small cell lung cancer.It is administered by intravenous infusion. Thedose-limiting toxicity is bone marrow suppression. |
| Definition | ChEBI: Gemcitabine is a 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It has a role as a photosensitizing agent, a DNA synthesis inhibitor, a prodrug, an EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, an environmental contaminant, a xenobiotic, a radiosensitizing agent, an antineoplastic agent, an antimetabolite, an antiviral drug and an immunosuppressive agent. It is an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside. |
| Manufacturing Process | Benzyl 4,6-O-benzylidene-2-O-benzyl-3-oxo-α-D-gluco-pyranoside wasobtained by 4 steps from glucose. 0.53 ml (4.0 mmol) of DAST (fluorinaiting agent) was added to asolution of300 mg (0.67 mmol) of benzyl 4,6-O-benzylidene-2-O-benzyl-3-oxo-α-Dgluco-pyranoside in anhydrous dichloromethane (4 ml). The solution was thenstirred at room temperature for 2 h, and the excess of DAST was neutralizedby careful addition of saturated aqueous NaHCO3. The resulting mixture wasextracted with CH2Cl2, and organic phase was dried and evaporated. Theresidue was purified by CC (Hexane/Ethyl acetate 7:1) to afford benzyl 4,6-Obenzylidene-2-O-benzyl-3-deoxy-3,3-difluoro-α-D-gluco-pyranoside (189 mg,60%), melting point 118°-119°C. Benzyl 4,6-O-benzylidene-2-O-benzyl-3-deoxy-3,3-difluoro-α-D-glucopyranoside (77 mg, 0.16 mmol) was dissolved in a 0.1 N solution of HCl inethanol and stirred at room temperature for 40 h. The solution was thenneutralized with solid NaHCO3, filtered and evaporated to give an oily productthat was dissolved in 2 ml of CH2Cl2 and 0.5 ml of pyridine. After cooling to0°C, 0.40 ml (1.6 mmol) of benzoyl chloride was added and the solution wasstirred for 1 h and poured into ice and water (200 ml) containing NaHCO3,extracted several times with CH2Cl2, dried and evaporated to give 86 mg(0.14 mmol, 90%) of benzyl 4,6-di-O-benzoyl-2-O-benzyl-3-deoxy-3,3-difluoro-α-D-gluco-pyranoside. Benzyl 4,6-di-O-benzoyl-2-O-benzyl-3-deoxy-3,3-difluoro-α-D-glucopyranoside (220 mg, 0.44 mmol) was dissolved in methanol in the presenceof 200 mg of palladium on activated charcoal (10% Pd content). Thesuspension was stirred at room temperature under hydrogen pressure (10bar) for 16 h. The suspension was then filtered through a thin silica gel pad,and evaporated. The residue was purified by CC to give 105 mg (59%) of 4,6-di-O-benzoyl-3-deoxy-3,3-difluoro-α/β-D-gluco-pyranoside as an inseparableanomeric mixture (ratio α/β = 5:1). To a solution of 46 mg (0.11 mmol) of 4,6-di-O-benzoyl-3-deoxy-3,3-difluoro-α/β-D-gluco-pyranoside in water-dioxane 1:2 (2 ml) was added 120 mg (0.56mmol) of sodium periodate. This resulting solution was stirred at roomtemperature for 20 h. Then, more sodium periodate (55 mg, 0.26 mmol) wasadded and stirring was continued for 6 h. After that, the solvents wereevaporated and the solid was repeatedly extracted with ethyl acetate (totalvolume 70 ml). The solvent was then evaporated to give a solid that wastreated for 15 min with a diluted (0.1%) methanolic solution of ammonia. THEsolution was evaporated and the crude purified by preparative TLC(hexane/ethyl acetate 2:1) to yield 18 mg (0.04 mmol, 43%) of α-3,5-di-Obenzoyl-2-deoxy-2,2-difluoro-D-ribose. |
| Therapeutic Function | Antineoplastic, Antiviral |
| General Description | The drug is available as the hydrochloride salt in 200- and1,000-mg lyophilized single-dose vials for IV use.Gemcitabine is used to treat bladder cancer, breast cancer,pancreatic cancer, and NSCLC. Gemcitabine is a potent radiosensitizer,and it increases the cytotoxicity of cisplatin.The mechanism of action of this fluorine-substituted deoxycytidineanalog involves inhibition of DNA synthesis andfunction via DNA chain termination. The triphosphatemetabolite is incorporated into DNA inhibiting severalDNA polymerases and incorporated into RNA inhibitingproper function of mRNA. Resistance can occur because ofdecreased expression of the activation enzyme deoxycytidinekinase or decreased drug transport as well as increasedexpression of catabolic enzymes. Drug oral bioavailabilityis low because of deamination within the GI tract, and thedrug does not cross the blood-brain barrier. Metabolism bydeamination to 2', 2'-difluorouridine (dFdU) is extensive.Drug toxicity includes myelosuppression, fever, malaise,chills, headache, myalgias, nausea, and vomiting. |
| Hazard | Human systemic effects |
| Mechanism of action | Gemcitabine showsgood activity against human leukemic cell lines,a number of murine solid tumors, and humantumor xenografts. Gemcitabine wassignificantly more cytotoxic than cytarabine inChinese hamster ovary cells. The major cellularmetabolite is the 5'-triphosphate of gemcitabine.The cytotoxicity was competitively reversed bydeoxycytidine, suggesting that the biologicalactivity required phosphorylation by deoxycytidine kinase. Tumor-bearing mice were treated with either gemcitabine or cytarabine (20 mg/kg). DNAsynthesis reached 1 % of control levels uponadministration of gemcitabine. The greateraccumulation of gemcitabine-5'-triphosphatecompared with cytarabine-5'-triphosphate maycause greater cytotoxicity and therapeutic activity. Further gemcitabine may enhance its own cytotoxic effects by self-potentiation mechanisms that act on, e. g., deoxycytidine monophosphatedeaminase, deoxycytidine kinase or on DNA synthesis. |
| Clinical Use | Antineoplastic agent: Palliative treatment, or first-line treatment withcisplatin, of locally advanced or metastatic non-smallcell lung cancer Pancreatic, ovarian and breast cancer Bladder cancer in combination with cisplatin |
| Drug interactions | Potentially hazardous interactions with other drugs Antipsychotics: avoid with clozapine, increased riskof agranulocytosis. |
| Metabolism | After intravenous doses gemcitabine is rapidly clearedfrom the blood and metabolised by cytidine deaminasein the liver, kidney, blood, and other tissues. Clearance isabout 25% lower in women than in men. Almost all (99%) of the dose is excreted in urine as2′-deoxy-2′,2′-difluorouridine (dFdU), only about1% being found in the faeces. Intracellular metabolismproduces mono-, di-, and triphosphate metabolites, thelatter two active. The active intracellular metabolites havenot been detected in plasma or urine. |
| references | [1] karnitz lm, flatten ks, wagner jm, et al. gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. mol pharmacol, 2005, 68 (6): 1636-1644. [2] ando t, ichikawa j, okamoto a, et al. gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. j orthop res, 2005, 23 (4): 964-969. [3] clouser cl, holtz cm, mullett m, et al. analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. plos one, 2011, 6 (1): e15840. |
Gemcitabine Preparation Products And Raw materials
| Raw materials | Dimethyl sulfate-->Ammonium sulfate-->Pyridine-->Sodium periodate-->Hydrogen-->Methyl 4,5-dimethoxy-2-nitrobenzoate-->Ozone-->Dimethyl sulfide-->Triethylamine-->N4-Acetylcytosine-->N,N-Diisopropylethylamine-->Hydrogen peroxide-->Titanium tetraisopropanolate-->Palladium hydroxide-->PHENYLSELENOL-->Trimethylsilyl trifluoromethanesulfonate |
| Preparation Products | Acelarin |
